Lear Werts partner Brad Lear has been appointed to a leadership role in In Re: Zantac (Ranitidine) Products Liability Litigation by Judge Rosenberg of the United States District Court for the Southern District of Florida. Judge Rosenberg appointed Brad to the Leadership Development Committee, an innovative leadership structure created by the Court to allow attorneys on the committee to “benefit from the mentorship and experience gained from participation in a large and complex MDL, and [for] the MDL [to] equally benefit from their enthusiasm and fresh perspective.”
The Leadership Development Committee is made up of five attorneys who the Court identified as having the potential “to become leaders within the MDL bar.” Asked about his appointment, Brad explained: “I am humbled and delighted to be among the attorneys named to the Leadership Development Committee. I look forward to working with—and learning from—the other attorneys appointed to the Plaintiff Leadership team and to doing my part to achieve a successful outcome for all of our clients.”
Prior to the consolidation of this case by the Joint Panel on Multidistrict Litigation (JPML), Lear Werts had filed a federal class action lawsuit in the United States District Court for the Western District of Missouri on behalf of a long-time Zantac user to recover economic damages under various consumer protection laws, including the Missouri Merchandising Practices Act.